Kodiak Sciences Inc
NASDAQ:KOD

  • LAST PRICE
    6.1900
  • TODAY'S CHANGE (%)
    0.2900 (4.9153%)
  • Bid / Lots
    5.6000/ 1
  • Ask / Lots
    6.2800/ 2
  • Open / Previous Close
    5.9000 / 5.9000
  • Day Range
    5.7900
    6.2800
  • 52 Week Range
    2.1850
    7.7700
  • Volume
    267,467

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 15, 2024

  • Nov 14, 2024

      Show headlines and story abstract

    • 4:02PM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: KOD
      04:02 PM EST, 11/14/2024 (MT Newswires) -- ...

    • 4:01PM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: KOD

      Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024.

      "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of where we stand today and where we are going - this is what I call 'Kodiak 2.0'. The video webcast includes scientific, clinical and commercial perspectives from key retina opinion leaders Dr. David Brown and Dr. Charles Wykoff. We encourage you to study these materials which are available on the Investors & Media page of our website."

    • 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: KOD

      of Kodiak Sciences Inc. in various global jurisdictions.
      Kodiak Sciences Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ------------------------ 2024 2023 2024 2023 ----------- ----------- ----------- ----------- Operating expenses Research and development $ 31,878 $ 36,188 $ 94,323 $ 159,669 General and administrative 14,754 18,312 46,347 54,278 ---------- ---------- ---------- ---------- Total operating expenses 46,632 54,500 140,670 213,947 ---------- ---------- ---------- ---------- Loss from operations (46,632) (54,500) (140,670) (213,947) Interest income 2,711 4,536 9,018 12,836 Interest expense -- (5) -- (13) Other income (expense), net (25) (38) (450) 149 ---------- ---------- ---------- ---------- Net loss $ (43,946) $ (50,007) $ (132,102) $ (200,975) ========== ========== ========== ========== Net loss per common share, basic and diluted $ (0.84) $ (0.95) $ (2.51) $ (3.84) ========== ========== ========== ========== Weighted-average shares of common stock outstanding used in computing net loss per common share, basic and diluted 52,616,183 52,455,620 52,560,489 52,391,083 ========== ========== ========== ========== Kodiak Sciences Inc. Condensed Consolidated Balance Sheet Data (in thousands) (Unaudited) September 30, December 31, 2024 2023 --------------- ------------ Cash and cash equivalents $ 197,864 $ 285,507 Working capital $ 178,433 $ 247,580 Total assets $ 372,669 $ 479,372 Accumulated deficit $ (1,284,633) $(1,152,531) Total stockholders' equity $ 185,370 $ 265,781

Peers Headlines